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ARTICLE
LRH-1 mitigates intestinal inflammatory disease by
maintaining epithelial homeostasis and cell survival
James R. Bayrer1,2, Hongtao Wang3, Roy Nattiv1, Miyuki Suzawa2, Hazel S. Escusa2, Robert J. Fletterick4,
Ophir D. Klein 5,6, David D. Moore7 & Holly A. Ingraham2
Epithelial dysfunction and crypt destruction are defining features of inflammatory bowel
disease (IBD). However, current IBD therapies targeting epithelial dysfunction are lacking.
The nuclear receptor LRH-1 (NR5A2) is expressed in intestinal epithelium and thought to
contribute to epithelial renewal. Here we show that LRH-1 maintains intestinal epithelial
health and protects against inflammatory damage. Knocking out LRH-1 in murine intestinal
organoids reduces Notch signaling, increases crypt cell death, distorts the cellular compo-
sition of the epithelium, and weakens the epithelial barrier. Human LRH-1 (hLRH-1) rescues
epithelial integrity and when overexpressed, mitigates inflammatory damage in murine and
human intestinal organoids, including those derived from IBD patients. Finally, hLRH-1 greatly
reduces disease severity in T-cell-mediated murine colitis. Together with the failure of a
ligand-incompetent hLRH-1 mutant to protect against TNFα-damage, these findings provide
compelling evidence that hLRH-1 mediates epithelial homeostasis and is an attractive target
for intestinal disease.
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Inflammatory bowel disease (IBD) is a chronic disorder that ischaracterized by bouts of intense gastrointestinal inflamma-tion, ultimately resulting in destruction of the epithelial lining
of the gut1. Although defects in genes expressed in the gut epi-
thelium have been associated with IBD2,3, the contribution of the
epithelium to this disease remains understudied, particularly in
comparison to the intensive interrogation of the immune com-
ponent. However, the recent establishment of mouse and human
intestinal organoids has provided an excellent experimental
platform to explore intrinsic epithelial defects in patients and
mouse models with disease4,5.
An important regulatory factor for intestinal epithelia is Liver
Receptor Homolog 1 (LRH-1, NR5A2). This nuclear receptor has
been shown to be expressed in intestinal crypts, where intestinal
stem cells (ISCs) reside6, and where it contributes to epithelial
renewal by potentiating WNT/β-catenin signaling6–8. Recent
GWAS meta-analyses of IBD patients found a significant asso-
ciation between LRH-1 and IBD9,10. Animal studies using het-
erozygous (Lrh-1+/−) or conditional knockout (Lrh-1fl/fl;
VilCreERT2) did not note any apparent epithelial defects at
baseline, but did report a defect in epithelial proliferation and
susceptibility to colitis6,11. Interestingly, the elimination of LRH-1
in mouse intestine and human colon cancer cell lines resulted in
decreased glucocorticoid production12–14, which has the potential
to lead to the kind of increased intestinal inflammation observed
in mouse models of colitis11,13. This atypical nuclear receptor
contains a well-ordered hormone-binding pocket, which binds
signaling phospholipids including phosphoinositides15–18. How-
ever, structural and biochemical studies have revealed major
differences between the human and mouse orthologs; hLRH-1
manifests a greater ligand-binding dependency15,17,19.
Here we investigate the physiological and pathophysiological
function of hLRH-1 in the intestinal epithelium. Using huma-
nized mouse intestinal organoids, a humanized in vivo IBD
model, and human intestinal organoids, we uncover an essential
role for LRH-1 in intestinal epithelial homeostasis and cell sur-
vival, which mitigates inflammatory injury. Our data rationalize
efforts required to target this nuclear receptor for the treatment of
IBD.
Results
LRH-1 maintains epithelial integrity and viability. In order to
investigate the role of LRH-1 in gut epithelia, LRH-1 expression
and the effects of its deletion were determined in mouse intestinal
organoids. Similar to prior in vivo studies6, mLrh-1 was found in
the crypt domain of intestinal organoids, but was also detected at
lower levels in the villus domain (Fig. 1a). Using Lrh-1fl/fl;Vil-
CreERT2 (Lrh1IEC-KO) mice, intestinal organoids were generated
following conditional and acute deletion of mLRH-1 (Fig. 1b).
Consistent with the proposed role for LRH-1 in Wnt/β−catenin-
regulated cell growth6, deletion of mLRH-1 increased cell death
and lowered organoid viability in a modified MTT reduction
assay20, compared to control organoids from Lrh1fl/fl mice
(Fig. 1c).
Transcriptional profiling of Lrh1fl/fl and Lrh1IEC-KO intestinal
organoids revealed significant gene changes in cell survival and
apoptosis pathways (Fig. 1d, e), suggesting a role for LRH-1 in
intestinal epithelial homeostasis and viability. Consistent with this
notion, a marked increase in activated Caspase 3 (Casp-3) was
observed in the intestinal crypt domain of Lrh1IEC-KO organoids,
which was further exacerbated by TNFα (Fig. 1f, g). As expected,
given the documented role of LRH-1 in intestinal epithelial
proliferation6,21, Lrh1IEC-KO intestinal organoids exhibited
decreased cell proliferation measured by 5-ethynyl-2-
deoxyuridine (EdU) incorporation (Supplementary Figure 1).
Because epithelial damage is a major contributor to chronic
inflammatory disease in IBD22, we investigated whether loss of
LRH-1 compromises the epithelial barrier. Indeed, significant
failure of the epithelial barrier was observed in Lrh1IEC-KO
intestinal organoids using a vital dye exclusion assay (Fig. 1h).
Together, these data support an essential role for LRH-1 in
epithelial viability and resilience.
LRH-1 affects crypt survival and differentiation via Notch.
Notch expression in the intestinal crypt preserves LGR5+ stem
cells while restricting secretory lineages and is critical for ISC
survival23,24. We then asked if the observed crypt cell death in
Lrh1IEC-KO organoids might arise from impairment in Notch
signaling. Indeed, both Notch1 transcripts and protein levels were
diminished in Lrh1IEC-KO organoids (Fig. 2a, b). Because Notch is
also a key factor in epithelial differentiation23,24, cell numbers and
markers for Paneth, goblet, and enteroendocrine cells (EECs)
were assessed after loss of LRH-1. As expected, lowered Notch
signaling in Lrh1IEC-KO organoids resulted in downregulation of
the stem cell markers Lgr5 and Olfm4, while leading to upregu-
lation of Lys and Muc-2; two respective markers for secretory
Paneth and goblet cells (Fig. 2b). The number of goblet cells
doubled in Lrh1IEC-KO intestines, and Paneth cells were visibly
expanded in intestinal crypts (Fig. 2c, d). Surprisingly, rather than
observing an expansion of EECs, as previously described with
Notch inhibition23,24, the number of enterochromaffin cells, a
representative sub-population of EEC cells, was significantly
reduced in Lrh1IEC-KO intestine (Fig. 2c, d), as were levels of EEC-
specific transcripts (Fig. 1d). Collectively, these data imply that
LRH-1 is necessary for maintenance of Notch signaling and cell
survival and for proper allotment of intestinal epithelial cell types.
Human LRH-1 prevents intestinal crypt death and TNFα
injury. We next asked whether restoring or overexpressing LRH-
1 might strengthen epithelial resilience to an inflammatory
challenge. Human LRH-1 (hLRH-1), rather than mLRH-1, was
chosen because it displays greater ligand-dependent activation
and is the relevant isoform in human disease. As illustrated in
Fig. 3a, hLRH-1, unlike mLRH-1, lacks the salt bridge at the
mouth of the ligand-binding pocket and requires a positive
charge to stabilize this domain15,25. This role is fulfilled by the
phosphate in the polar head group of its phospholipid ligand.
Expression of hLRH-1 in mouse intestinal organoids was
achieved by an AAV8-mediated infection protocol, which was
optimized using AAV8-GFP. This method resulted in rapid and
efficient gene expression (Fig. 3b) that persisted for the life of the
epithelial cell (Supplementary Figure 2) and permitted dosing that
could either match or exceed endogenous levels of mLRH-1
(Fig. 3c, left). Nuclear expression of hLRH-1 was detected
throughout the crypt and villus zones (Fig. 3b).
Human LRH-1 expression was able to fully rescue crypt cell
death and maintain viability in Lrh1IEC-KO organoids even upon
challenge by TNFα (Fig. 3d–f). To ascertain if ligand binding is
necessary for hLRH-1-mediated rescue, we next attempted to
salvage organoid viability with the well-characterized ligand-
binding-defective variant of hLRH-1 (PM; Fig. 3a)26,27. Bulky
hydrophobic residues were modeled in the binding pocket to
impede ligand uptake without effecting protein integrity, as
previously demonstrated in cultured cell lines26. Indeed, the
human PM variant is stably expressed in intestinal organoids
(Fig. 3c, right), and despite the fact that the hPM retains modest
transcriptional activity26,27, it failed to rescue TNFα-induced cell
death in Lrh1IEC-KO intestinal organoids (Fig. 3f, light blue bar).
Expressing hLRH-1 resulted in upregulation of known down-
stream targets including Shp, Cyp11a1, and Cyp11b1 as well as
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robust expression of new potential LRH-1 targets (Ctrb1 and
Smcp), and mediators of cell survival and anti-inflammatory
responses, including the decoy receptors Il1rn and Tnfrsf23 and
the antiapoptotic factor Hmox1 (Fig. 3g and Supplementary
Figures 3 and 4). Adding hLRH-1 to Lrh1IEC-KO organoids also
restored the integrity of the epithelial barrier, as demonstrated by
a reduction of vital dye-positive organoids (Fig. 3h). Moreover,
increasing the dosage of hLRH-1 in the presence of wild-type
mLRH-1 ameliorated TNFα-induced cell death, suggesting that
elevated LRH-1 activity protects against inflammatory damage
(Fig. 3i, left). This effect extends to other epithelial insults, as
overexpression of hLRH-1 also protected against damage by
fluorouracil (5-FU), a common chemotherapeutic with intestinal
toxicity (Fig. 3i, right). Taken together, these data demonstrate
that hLRH-1 fully substitutes for mLRH-1 to restore cell survival
and activate anti-inflammatory programs.
To confirm the survival role of LRH-1 in vivo, we used a
humanized intestinal mouse model in which mLRH-1 is deleted
and hLRH-1 expressed in an inducible Cre-dependent manner
(referred to as hLRH1IEC-Flex). Despite the lower protein levels of
hLRH-1 as compared to endogenous mLRH-1 in hLRH1IEC-Flex
organoids (Fig. 4a), expressing hLRH-1 reduced cell death by
nearly 50% and restored Ctrb1 levels (Fig. 4b, c). These ex vivo
results were confirmed in vivo by the near absence of cleaved
Casp3 in intestinal crypts of the ileum (and to a lesser extent in
villi) in hLRH1IEC-Flex mice compared to Lrh1IEC-KO (Fig. 4d).
Taken together, these data reveal that human LRH-1 can promote
cell survival in murine intestinal epithelia lacking mLRH-1 and
following challenge by TNFα.
hLRH-1 ameliorates an immune-mediated colitis mouse
model. To determine whether increased levels of LRH-1 can
improve the course of disease in an immune-mediated model of
colitis, VilCre;Rag2−/−;Rosa26-Flox-Stop-Flox hLRH-1 mice
(Rag2−/−hLrh1IEC-TG) were generated to conditionally over-
express hLRH-1 in the intestinal epithelium in the presence of
endogenous mLRH-1. As expected from our earlier data, mLRH-
1 elimination greatly exacerbated T-cell transfer (TcT)-induced
colitis in Rag2−/−hLrh1IKO male mice (Fig. 5a). Significantly, this
result was markedly different after overexpressing hLRH-1. Dis-
ease severity was largely mitigated in Rag2−/−hLrh1IEC-TG mice,
as evidenced by the relative preservation of body weight, pro-
longed disease-free survival, improved colitis histology scores,
and reduced disease activity index (DAI). In fact, nearly all dis-
ease parameters were better in Rag2−/−hLrh1IEC-TG animals
relative to animals expressing endogenous mLRH-1 (Fig. 5a).
Mirroring this improvement in colitis, Rag2−/−hLrh1IEC-TG ani-
mals showed a decreased inflammatory cytokine profile, with
lower intestinal expression of TNFα, IL-1β, and IL-6, and a
corresponding increase in the anti-inflammatory cytokine IL-10
(Fig. 5b). Collectively, these in vivo data establish the critical role
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of LRH-1 as an anti-inflammatory agent in the intestinal
epithelium.
LRH-1 protects human intestinal organoids from TNFα injury.
To determine whether the anti-inflammatory and prosurvival
activity of LRH-1 translates to the human intestinal epithelium,
human small intestinal organoids were derived from endoscopic
biopsy samples of ileum from both Crohn disease patients and
healthy individuals (Fig. 6a). Unlike murine small intestinal
organoid cultures, human-derived organoids are maintained in a
partially differentiated state, consisting of intestinal stem cells and
partially differentiated Paneth cells, and undergo differentiation
following WNT withdrawal4. Human Lrh1 is expressed at similar
levels in both differentiated and undifferentiated human orga-
noids (Supplementary Figure 5), and remains broadly distributed
throughout the epithelium following differentiation, as confirmed
by staining for secretory goblet (MUC2) and Paneth (LYZ) cells
(Fig. 6b). This pattern closely matches the broad distribution of
murine Lrh1 (Fig. 1a).
Increasing hLRH-1 dosage by AAV-mediated infection caused
an upregulation of the LRH-1 target Ctrb1 (Fig. 6c). Importantly,
in human organoids from both healthy individuals and Crohn
disease patients, overexpression of hLRH-1 abrogated TNFα-
induced cell death (Fig. 6d). Taking all the data in this study
together, we conclude that LRH-1 plays an essential role in
intestinal homeostasis and in ameliorating inflammation-induced
injury in human intestinal epithelia.
Discussion
In this study, using multiple independent mouse and human
ex vivo and in vivo intestinal models, we establish that the nuclear
receptor LRH-1 (Nr5a2) has a crucial role in maintaining the
intestinal epithelium. Acutely knocking out mLRH-1 resulted in
decreased Notch signaling and increased cell death in the
intestinal crypt. Importantly, humanization of the mouse intest-
inal epithelium by expression of hLRH-1 corrected these deficits.
Moreover, overexpression of hLRH-1 in both mouse and human
intestinal organoids imparted epithelial resistance to both TNFα,
a major inflammatory cytokine in IBD, and 5-FU, a chemother-
apeutic with intestinal toxicity. In the intact animal, expression of
hLRH-1 ameliorated immune-mediated colitis. Using a viral-
mediated approach newly applied to intestinal organoids, we
showed that efficient rescue by hLRH-1 is ligand dependent.
These findings are important because they provide a compelling
argument that drug targeting of LRH-1 could enhance resistance
to inflammation and restore intestinal epithelial health in
intestinal diseases such as IBD.
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Our study extends prior studies, reporting impaired cell
renewal and enhanced chemical-induced colitis in heterozygous
and conditional knockout mice, by demonstrating both a fun-
damental role for LRH-1 in the maintenance of epithelial viability
and cell types, and the therapeutic potential of LRH-1 in intest-
inal disease. Further, we reveal that acute loss of mLRH-1 disrupts
Notch expression, triggers increased apoptosis in the crypt and
results in a breach in the epithelial barrier. Our data are con-
sistent with the findings by Samuelson and colleagues that
attenuating Notch signaling by genetic or pharmacological
methods resulted in significant ISC apoptosis, crypt disruption,
and expansion of secretory lineages. Interestingly, loss of LRH-1
not only recapitulates these findings, but also appears to com-
promise cells outside of the crypt base. We hypothesize that
intestinal crypt apoptosis hinders renewal of the intestinal lining
and exacerbates the immune inflammatory response3. In support
of this idea, we demonstrate that loss of intestinal LRH-1
expression is associated with diminished animal survival and
increased intestinal inflammation in the T-cell transfer model of
colitis. Importantly, increased hLRH-1 has a clear beneficial
impact on disease activity and colitis scores, consistent with our
organoid models.
The ability to acutely knock out mLRH-1 and replenish with
hLRH-1 in intestinal organoids has provided new insights into
the identity and function of species-specific LRH-1 targets in the
small intestine. Based on the rapid crypt cell death and spectrum
of differentially expressed genes, cell survival is the most pro-
minent pathway affected following acute loss of mLRH-1. Inter-
estingly, despite the known species difference in ligand binding15,
hLRH-1 not only functionally complements mLRH-1 but also
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upregulates anti-inflammatory genes. hLRH-1 enhances Il1rn and
Tnfrsf23, which act as decoy receptors for circulating proin-
flammatory cytokines. Rdh9 (retinol dehydrogenase) was also
upregulated threefold by hLRH-1; interestingly, this gene is also
increased in the intestine of conventional as opposed to germ-free
mice28. Ctrb1, encoding chymotrypsin, and Smcp appear to be
two highly sensitive markers of LRH-1 activity that are robustly
activated by hLRH-1 in both mice and human intestinal orga-
noids. It is known that LRH-1 binds the proximal promoter of
Ctrb129, raising the possibility that fecal chymotrypsin may serve
as a biomarker to assess and follow pharmacological manipula-
tion of hLRH-1 activity in vivo. Finally, ex vivo and in vivo mouse
models of enteritis, in which mLRH-1 is replaced with the human
form that binds signaling phospholipids more efficiently15,26,30,
will provide a valuable platform to test and probe the utility of
any synthetic ligands.
Our data suggest that LRH-1 may play a previously unappre-
ciated role in epithelial cell differentiation in the intestine, in
addition to ISC maintenance. Indeed, a similar role for LRH-1 has
been reported in the pancreas29,31 and recently in neural stem
cells32. Interestingly, although we observe an increase in secretory
Paneth and goblet cells, consistent with reduction of Notch sig-
naling, loss of LRH-1 also leads to a significant drop in markers
defining nearly all subclasses of EECs33. These data infer separate
but positive roles for LRH-1 in Notch intestinal crypt signaling
and EEC differentiation. Intriguingly, the latter effect may be
regional, with the greatest loss of EEC cells following deletion of
LRH-1 in the ileum and proximal colon (J.B. and H.I., unpub-
lished data); both of which exhibit high LRH-1 expression6. An
understanding of how and where LRH-1 promotes lineage
commitment in the gastrointestinal tract remains to be
determined.
An important unanswered question is whether increased LRH-
1 expression drives unchecked proliferation and promotes dys-
plasia in the intestinal epithelium, as suggested previously.
Indeed, an earlier study showed that LRH-1 haploinsufficiency
reduced tumor burden in the APCMIN model, possibly through
interactions with the Wnt pathway at the Cyclin D1 and Cyclin E1
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promoters8, but this same study noted decreased Lrh1 in intest-
inal tumors. While our studies with the nonreplicating AAV
vector preclude us from exploring the question of cell prolifera-
tion in infected intestinal organoids, we note that neither Cyclin
D1 nor Cyclin E1 were changed after loss of mLRH-1 or
expression of hLRH-1 (Supplementary Figure 4).
The findings presented here leverage a new use for AAV-
directed gene expression to rapidly manipulate small intestinal
organoids. Positive features of AAV infection, versus classical
lentiviral transduction, are the high infectivity, rapid onset of
gene expression, and the ability to infect large organoid frag-
ments. On the other hand, the nonreplicating nature of AAV
restricts expression to the typical ~7 days turnover for mouse
intestinal organoids. Nonetheless, this system allows a rapid
structure−function analysis by simultaneously knocking out and
adding back variants, which we put to effective use in this study
to show the ligand-dependency of hLRH-1 effects. As unique
molecular signatures of intestinal epithelial subtypes continue to
emerge33,34, engineering cell-specific promoters into the AAV-
system should allow a more granular functional assessment of
individual intestinal epithelial cell types.
In summary, our study of human intestinal organoids, huma-
nized murine intestinal organoids, and a humanized murine IBD
model show that LRH-1 promotes normal intestinal epithelial
homeostasis and can be leveraged protectively against intestinal
inflammation.
Methods
Study approval. Animal studies were conducted in accordance with IACUC
guidelines in strict accordance with the recommendations in the Guide for the Care
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and Use of Laboratory Animals of the National Institutes of Health. All animal
studies and procedures were approved by the Baylor College of Medicine (AN-
1550) and UCSF (AN173604-01A) Institutional Animal Care and Use Committee.
All human studies were reviewed and approved by the UCSF Institutional Review
Board (IRB 15-17763) and utilized tissue from deidentified donors who had given
written informed consent to the study.
Animal experiments. Animals were housed and bred in SPF facility. Inducible IEC
knockout line was created by crossing animals harboring CreERT2 under control
of the villin promoter with Lrh1fl/fl animals and bred to homozygosity. Lrh1IEC-Flex
line was generated with Lox-STOP-Lox-hLRH1 animals, gift of DeMayo (Baylor
College of Medicine) crossed into our Lrh1IEC-KO line. For animal knockout and
activation studies, tamoxifen was dissolved in sunflower oil and delivered by two
intraperitoneal injections 48 h apart (1 mg per day). Mice were sacrificed and tissue
collected 5 days following the last tamoxifen dose. For the T-cell transfer model,
Lrh1fl/f;VilCre animals were bred with Rag2−/− (Jackson Laboratory) to homo-
zygosity to generate Rag2−/− Lrh1IEC-KO animals. Likewise, Rosa26-Flox-Stop-Flox
hLRH-1;VilCre animals were crossed with Rag2−/− animals to generate Rag2−/−
hLRH1IEC-TG animals. Chronic enterocolitis was induced by T-cell transfer of
0.5 million naive T cells per mouse, as described35. Briefly, wild-type splenic
CD4+CD45RBhigh cells were isolated by MACS separation and flow cytometry cell
sorting (Supplementary Figure 6), and then transferred by intraperitoneal injection
to Rag2−/− mice.
Clinical DAI and colon colitis scores: To assess the clinical DAI body weight
loss, diarrhea, guaiac-positive hematochezia, and appearance were monitored daily
during the experiment. The DAI was determined according to a published scoring
system36 (Supplementary Table 1). For colon histological analysis, the colon was
divided into three segments (proximal third, middle third, and distal third). Each
segment was embedded in paraffin, sectioned at 5 μm, and stained with
hematoxylin and eosin. Histological analysis was performed in the Cellular and
Molecular Morphology Core of the Digestive Disease Center at Baylor College of
Medicine. The sections were blindly scored using a standard histologic colitis
score37. Three independent parameters were measured: severity of inflammation
(0–3: none, slight, moderate, severe), depth of injury (0–3: none, mucosal, mucosal
and submucosal, transmural), and crypt damage (0–4: none, basal one-third
damaged, basal two-thirds damaged, only surface epithelium intact, entire crypt
and epithelium lost). The score of each parameter was multiplied by a factor
reflecting the percentage of tissue involvement (×1, 0–25%; ×2, 26–50%; ×3,
51–75%; ×4, 76–100%) averaged per colon.
Crypt culture. Intestinal crypt cultures were derived from Lrh1fl/fl, VilCreERT2;
Lrh1fl/fl, and VilCreERT2;Lrh1fl/fl;RosahLRH1 6-week-old male mice. Briefly, the
small intestine was isolated and flushed with ice-cold phosphate-buffered saline
(PBS) and opened longitudinally. Villi were mechanically removed and the intes-
tine cut into 1–2 mm pieces. Intestinal fragments were then incubated in an EDTA
containing solution at 4 °C for 30 min. The intestinal fragment suspension was
fractionated and crypt-containing fractions passed through a 70-μm cell strainer
for plating in Matrigel. Crypt-Matrigel suspension was allowed to polymerize at
37 °C for 10 min. Intestinal organoids were grown in base culture media (Advanced
DMEM/F12 media, HEPES, GlutaMax, penicillin, and streptomycin) supple-
mented with growth factors (EGF, Noggin, R-spondin; Peprotech), B27 (Life
Technologies), N2 (Life Technologies), and N-acetyl cysteine (NAC; Sigma). To
activate genetic recombination, (Z)-4-hydroxytamoxifen (4OHT; Sigma) was
added at 300 nM for 48 h.
Human intestinal organoid culture. Endoscopic biopsy samples obtained from
the terminal ileum were processed under a dissecting microscope to liberate
intestinal crypts using EDTA chelation and mechanical disruption. Crypts were
screened through a 100 μm filter, centrifuged, and suspended in ice-cold Matrigel.
The suspension was plated on prewarmed cell culture plates. Following poly-
merization of Matrigel, propagation media (50% LWRN conditioned media from
ATCC CRL-3276, supplemented with human EGF (Peprotech), A-83-01 (Tocris),
SB202190 (Sigma), Gastrin (Sigma), Nicotinamide (Sigma), B27 (Life Technolo-
gies), N2 (Life Technologies), GlutaMax (Life Technologies), and HEPES (Sigma)
in F12 Advanced DMEM (Life Technologies)) was added. For the first 48 h of
culture, CHIR99021 (Stemgent) and thiazovin (Stemgent) were added to support
stem cell growth. To induce differentiation, media was replaced with differentiation
media (consisting of base culture media supplemented with 10% R-Spondin con-
ditioned media, human EGF (Peprotech), human Noggin (Peprotech), A-83-01,
Gastrin, NAC, B27, and N2).
Expression analysis. Immunofluorescence (IF) and RNA in situ hybridization
were performed on 5 μm cryosections using standard procedures. DIG-labeled
(Roche) riboprobes were generated from pCRII-TOPO plasmid (ThermoFisher
Sci) with mLRH-1 cDNA corresponding to bases 595–1683. Antibodies against
hLRH-1 (1:200, Sigma HPA005455), FLAG (1:300, Sigma F7425), cleaved Caspase-
3 (1:1000 (WB) and 1:400 (IF), Cell Signaling 5A1E), CD-44 (1:500, Tonbo 70-
0441), lysozyme (1:200, DAKO EC 3.2.1.17) and MUC-2 (1:300, Santa Cruz Bio-
technology sc-15334) were used with Alexa Fluor-conjugated secondary antibodies
1:300 (Millipore, Invitrogen). For Goblet staining, Rhodamine-labeled Dolichos
Biflorus Agglutinin (Vector Labs) was used at 1:200 dilution.
RNA isolation and PCR. Intestinal organoids were washed in ice-cold PBS and
suspended in Trizol solution (Ambion). RNA was isolated with Direct-zol spin
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columns (Zymo Research). DNAse-treated total RNA was used to generate cDNA
using Superscript II (Invitrogen). Sybr green-based qPCR (Quanta) was performed
on an Applied Biosystems Model 7900HT with primers as per Supplementary
Table 2. The ΔΔCt method was used for calculation of gene expression using
Gapdh as reference. For RNA-Seq studies, RNA was isolated on Day 4 following
AAV infection. Ovation RNA-Seq System V2 (NuGEN) was used to generate the
cDNA library for sequencing on an Illumina HiSeq 4000. Data were analyzed using
the GALAXY program suite38. Pathway analysis and annotations were performed
with Ingenuity IPA (Qiagen) and Genecodis39, respectively. For colitis experiments,
total RNA was isolated from snap-frozen colon tissues using Trizol Reagent
(Invitrogen) and cDNA prepared with qScriptTM cDNA Synthesis Kit (Quanta
Biosciences). Colonic gene expression was determined by qPCR using SYBR Green
master (Kapa Biosystems Inc.). mRNA levels were normalized by the 36B4 gene
expression. Prevalidated primers for qPCR were purchased from Qiagen (https://
www.qiagen.com/geneglobe/default.aspx).
Viability and proliferation assays. Murine intestinal organoids were plated in 10
μl Matrigel drops onto a prewarmed 96-well cell culture plate and following
polymerization 100 μl prewarmed organoid growth media was added. Following
Cre activation with 300 nM 4OH-tamoxifen, cultures were incubated with mTNFα
for 40 h. Viability was assessed by a modified 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) reduction assay as described18. Briefly,
intestinal organoids were incubated with 500 μg/ml MTT for 2 h at 37 °C. Media
was aspirated and Matrigel dissolved in 2% SDS for 2 h at 37 °C with shaking. MTT
was then solubilized in DMSO and absorbance measured at OD562. To normalize
for crypt seeding and background drop-out, data were normalized by resazurin
where indicated in the text. Here, intestinal organoids were incubated with resa-
zurin (10 μg/ml) for 6 h prior to administration of mTNFα. Media was removed
and fluorescence measured (excitation 530 nm, emission 590 nm) and used to
normalize MTT values20. Experiments were repeated a minimum of three times
with five replicates per experiment. For human intestinal organoids, plates were set
as above and organoids grown initially in propagation media for 24 h to establish
organoids and then switched to differentiation media for the remainder of the
experiment. Human TNFα was added after 72 h. Viability was determined by MTT
40 h after TNFα administration.
For proliferation studies, intestinal organoid cultures were incubated with EdU
(10 μM) for 2 h and then fixed in 4% paraformaldehyde. Click-It chemistry was
performed as per the manufacturer’s recommendations on 5 μm cryosections (Life
Technologies). For 5-FU experiment, organoids were incubated with 5-FU (5 μg/ml
in DMSO; Millipore) for 24 h and viability determined as above.
Immunoblotting. Protein was isolated from intestinal organoids grown in 24-well
culture plates in RIPA buffer containing protease inhibitors (Roche). Samples were
processed in a Biorupter prior to gel loading. Antibodies include LRH-1 (R&D
Systems PP-H2325-00), β-Actin (Ambion AM4302), FLAG (Sigma F1804), cleaved
Caspase-3 (Cell Signaling 5A1E), and cleaved Notch1 (Cell Signaling D3B8). Full
blots are shown in Supplementary Materials (Supplementary Figure 7).
Dextran exclusion assay. Intestinal organoids were exposed to mTNFα for 24 h
and then incubated in 1 mg/ml Texas Red labeled dextran (average weight 10 kDa;
Life Technologies) for 30 min. Following incubation, excess dye was removed by
serial washes with PBS and the plate imaged immediately. Wells were scored for
fraction of dye-retaining intestinal organoids. 30–50 intestinal organoids were
seeded per well. Eight wells per experiment were scored for each condition. Opened
intestinal organoids were excluded from analysis. Results were validated by a
blinded, independent observer.
AAV-directed gene expression. AAV viral particles expressing hLRH1 or GFP
under direction of the thyroxine-binding globulin promoter were obtained from
the University of Pennsylvania Viral Core. Intestinal organoids were isolated in
cold PBS, pelleted at 1000 × g, and resuspended in ice-cold Matrigel. The mixture
was added to chilled Eppendorf tubes containing virus on wet ice and then ali-
quoted immediately onto prewarmed cell culture plates. After Matrigel was set,
organoid growth media was added.
Imaging. Live cell and intestinal organoid immunofluorescence imaging was per-
formed on an Olympus IX51 microscope equipped with a DP71 imager. Mouse
intestinal imaging was obtained on a Nikon Eclipse Ti equipped with a DS-Qi2
imager or an Olympus BX40 microscope with Magnafire imager.
Data availability
Deep sequencing data are archived under GEO accession number GSE116563. Reagents
including mouse and organoid lines will be made available by request.
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